Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CET Company also expects to publish third quarter 2025 financial results on the same day p
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
07:20am, Tuesday, 21'st Oct 2025
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:30am, Friday, 12'th Sep 2025
JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company�
InflaRx Announces Participation in September Investor Conferences
07:30am, Thursday, 21'st Aug 2025
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
09:45am, Thursday, 07'th Aug 2025
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate.
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
07:30am, Thursday, 07'th Aug 2025
JENA, Germany, Aug. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
07:30am, Thursday, 31'st Jul 2025
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
04:15pm, Friday, 11'th Jul 2025
JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
11:00am, Wednesday, 28'th May 2025
InflaRx N.V. IFRX on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosu
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
01:30am, Wednesday, 28'th May 2025
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced t
InflaRx to Participate in Upcoming Investor Conferences
07:30am, Thursday, 22'nd May 2025
JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced t
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
07:30am, Wednesday, 07'th May 2025
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced i
InflaRx to Report First Quarter 2025 Results on May 7, 2025
07:30am, Wednesday, 30'th Apr 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Wednesday, 26'th Mar 2025
InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
07:30am, Thursday, 20'th Mar 2025
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
